Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Cereblon Is Downregulated By Promoter Nucleosome Occupancy in Acquired IMiD Resistance: The Potential of IMiD Resensitization By Epigenetic Therapy

Konstantinos Dimopoulos, MD, Peter Gimsing, MD PhD, Gangning Liang, Kirsten Grønbæk, Alexandra Helbo Søgaard, Ranjani Lakshminarasinham

Blood (2016) 128 (22): 3258.

https://doi.org/10.1182/blood.V128.22.3258.3258

Published: 2016

Journal Articles

GDF15 Promotes Osteoclast Differentiation and High Serum GDF15 Levels Are Associated with Multiple Myeloma Bone Disease

Marita Westhrin, MSc, Siv Helen Moen, PhD, Toril Holien, PhD, Oddrun Elise Olsen, MSc, Anne Kærsgaard Mylin, MDhD, Peter Gimsing, MD PhD, Ingemar Turesson, MD PhD, Anders Waage, MD PhD, Therese Standal, PhD

Blood (2014) 124 (21): 2065.

https://doi.org/10.1182/blood.V124.21.2065.2065

Published: 2014

Journal Articles

Safety and Efficacy of Daratumumab with Lenalidomide and Dexamethasone in Relapsed or Relapsed, Refractory Multiple Myeloma

Torben Plesner, MD, Hendrik-Tobias Arkenau, MD, Henk M. Lokhorst, MDPhD, Peter Gimsing, MD PhD, Jakub Krejcik, MD, Charlotte Lemech, MD, Monique C. Minnema, MDPhD, Ulrik Lassen, MDPhD, Jacob P. Laubach, MD, Tahamtan Ahmadi, MD PhD, Howard Yeh, MD, Mary E Guckert, MSN, RN, Huaibao Feng, Nikolai Constantin Brun, MDPhD, Steen Lisby, Linda Basse, MDDMSc, Antonio Palumbo, MD, Paul G. Richardson

Blood (2014) 124 (21): 84.

https://doi.org/10.1182/blood.V124.21.84.84

Published: 2014

Journal Articles

Daratumumab, a CD38 Monoclonal Antibody in Patients with Multiple Myeloma - Data From a Dose-Escalation Phase I/II Study

Torben Plesner, MD, Henk Lokhorst, MD, PhD, Peter Gimsing, MD, PhD, Hareth Nahi, Steen Lisby, MD, DMSc, Paul G. Richardson, MD

Blood (2012) 120 (21): 73.

https://doi.org/10.1182/blood.V120.21.73.73

Published: 2012

Journal Articles

Does Heparin Have An Anti-Myeloma Effect? An Analysis On Individual Data From Three Randomized Studies of GIMEMA, Nordic and Turkish Myeloma Study Groups,

Meral Beksac, MD, Anders Waage, MD, PhD, Sara Bringhen, MD, Sigurdur Y Kristinsson, MD PhD, Gulsan Sucak, MD, Peter Gimsing, MD, PhD, Lupparelli Giulia, PhD, Tulin Firatli Tuglular, MD, Gunnar Juliusson, MD PhD, Antonio Palumbo, MD

Blood (2011) 118 (21): 3970.

https://doi.org/10.1182/blood.V118.21.3970.3970

Published: 2011

NARROW

Cereblon Is Downregulated By Promoter Nucleosome Occupancy in Acquired IMiD Resistance: The Potential of IMiD Resensitization By Epigenetic Therapy

GDF15 Promotes Osteoclast Differentiation and High Serum GDF15 Levels Are Associated with Multiple Myeloma Bone Disease

Safety and Efficacy of Daratumumab with Lenalidomide and Dexamethasone in Relapsed or Relapsed, Refractory Multiple Myeloma

Daratumumab, a CD38 Monoclonal Antibody in Patients with Multiple Myeloma - Data From a Dose-Escalation Phase I/II Study

Does Heparin Have An Anti-Myeloma Effect? An Analysis On Individual Data From Three Randomized Studies of GIMEMA, Nordic and Turkish Myeloma Study Groups,

Email alerts

ASH Publications

American Society of Hematology

Cereblon Is Downregulated By Promoter Nucleosome Occupancy in Acquired IMiD Resistance: The Potential of IMiD Resensitization By Epigenetic Therapy

GDF15 Promotes Osteoclast Differentiation and High Serum GDF15 Levels Are Associated with Multiple Myeloma Bone Disease

Safety and Efficacy of Daratumumab with Lenalidomide and Dexamethasone in Relapsed or Relapsed, Refractory Multiple Myeloma

Daratumumab, a CD38 Monoclonal Antibody in Patients with Multiple Myeloma - Data From a Dose-Escalation Phase I/II Study

Does Heparin Have An Anti-Myeloma Effect? An Analysis On Individual Data From Three Randomized Studies of GIMEMA, Nordic and Turkish Myeloma Study Groups,

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only